Peptide profiling of cerebrospinal fluid by mass spectrometry

Expert Review of Proteomics

Volumn 3, Issue 3, 2006, Pages 297-309

  Dekker, Lennard J ^a   Burgers, Peter C ^a   Kros, Johan M ^a   Sillevis Smitt, Peter A E ^a   Luider, Theo M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; MALDI FT ion cyclotron resonance; MALDI TOF; Mass spectrometry; Peptide profiling; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; PEPTIDE; PROSTATE SPECIFIC ANTIGEN;

AMINO ACID SEQUENCE; BODY FLUID; CEREBROSPINAL FLUID; DATA BASE; DISEASE ACTIVITY; FOURIER TRANSFORM MASS SPECTROMETRY; FRACTIONATION; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL EXPERT; MEDICAL INSTRUMENTATION; MICROARRAY ANALYSIS; PATHOGENESIS; PEPTIDE ANALYSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; VALIDATION STUDY;

BIOLOGICAL MARKERS; CEREBROSPINAL FLUID PROTEINS; DIAGNOSIS; HUMANS; MASS SPECTROMETRY; PEPTIDES;

EID: 33745570109     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.3.3.297     Document Type: Review

References (85)

1. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 563, 23-60 (2005). Discusses dynamic range issues of plasma and how to solve this with candidate-based proteomics.
2. de Boer E, Rodriguez P, Bonte E et al. Efficient biotinylation and single-step purification of tagged transcription factors in mammalian cells and transgenic mice. Proc. Natl Acad. Sci. USA 100, 7480-7485 (2003).
3. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 405, 837-846 (2000).
4. Kravchick S, Peled R, Dorfman D, Agulansky L, Ben-Dor D, Cytron S. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/ml. Urology 66, 542-546 (2005).
5. Jacobs IJ, Skates S, Davies AP et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. Br. Med. J. 313, 1355-1358 (1996).
6. Felgenhauer K. Protein size and cerebrospinal fluid composition. Klin. Wochenschr. 52, 1158-1164 (1974).
7. Fishman RA. Cerebrospinal Fluid in Diseases of the Nervous System. WB Saunders Company, PA, USA, (1992).
8. Reiber H. CSF Flow - its Influence on CSF Concentration of Brain-Derived and Blood-Derived Proteins. Plenum, NY, USA, (1997).
9. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta 310, 173-186 (2001).
10. Zheng PP, Luider TM, Pieters R et al. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J. Neuropathol. Exp. Neurol. 62, 855-862 (2003).
11. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol. Neurobiol. 24, 87-97 (2001).
12. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26, 231-245 (1995).
13. Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EF III, Liotta LA. CSF proteome: a protein repository for potential biomarker identification. Expert Rev. Proteomics 2, 57-70 (2005).
14. Omenn GS, States DJ, Adamski M et al. overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5, 3226-3245 (2005). Overview of the results of the Human Proteome Organization Plasma Proteome Project.
15. Govorukhina NI, Keizer-Gunnink A, van der Zee AG, de Jong S, de Bruijn HW, Bischoff R. Sample preparation of human serum for the analysis of tumor markers. Comparison of different approaches for albumin and γ-globulin depletion. J. Chromatogr. A 1009, 171-178 (2003).
16. Zolotarjova N, Martosella J, Nicol G, Bailey J, Boyes BE, Barrett WC. Differences among techniques for high-abundant protein depletion. Proteomics 5, 3304-3313 (2005).
17. Fromell K, Andersson M, Elihn K, Caldwell KD. Nanoparticle decorated surfaces with potential use in glycosylation analysis. Colloids Surf. B Biointerfaces 46, 84-91 (2005).
18. Garcia BA, Shabanowitz J, Hunt DF. Analysis of protein phosphorylation by mass spectrometry. Methods 35, 256-264 (2005).
19. Mehta AI, Ross S, Lowenthal MS et al. Biomarker amplification by serum carrier protein binding. Dis. Markers 19, 1-10 (2003).
20. Lowenthal MS, Mehta AI, Frogale K et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin. Chem. 51, 1933-1945 (2005).
21. Rieux L, Lubda D, Niederlander HA, Verpoorte E, Bischoff R. Fast, highefficiency peptide separations on a 50-mum reversed-phase silica monolith in a nanoLC-MS set-up. J. Chromatogr. A (2006) (In Press).
22. Wienkoop S, Glinski M, Tanaka N, Tolstikov V, Fiehn O, Weckwerth W. Linking protein fractionation with multidimensional monolithic reversed-phase peptide chromatography/mass spectrometry enhances protein identification from complex mixtures even in the presence of abundant proteins. Rapid Commun. Mass Spectrom. 18, 643-650 (2004).
23. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002).
24. Rogers MA, Clarke P, Noble J et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res. 63, 6971-6983 (2003).
25. Grizzle WE, Adam BL, Bigbee WL et al. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis. Markers 19, 185-195 (2003).
26. Malik G, Ward MD, Gupta SK et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin. Cancer Res. 11, 1073-1085 (2005).
27. Soltys SG, Shi G, Tibshirani R, Giaccia AJ, Koong AC, Le Q. The use of plasma SELDI-TOF MS proteomic patterns for detection of head and neck squamous cell cancers (HNSCC). Int. J. Radiat. Oncol. Biol. Phys. 57, S202 (2003).
28. Lewczuk P, Esselmann H, Meyer M et al. The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Aβ peptide. Rapid Commun. Mass Spectrom. 17, 1291-1296 (2003).
29. Lewczuk P, Esselmann H, Groemer TW et al. Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol. Psychiatry 55, 524-530 (2004).
30. Ruetschi U, Zetterberg H, Podust VN et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp. Neurol. 196, 273-281 (2005).
31. Carrette O, Demalte I, Scherl A et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3, 1486-1494 (2003).
32. Ranganathan S, Williams E, Ganchev P et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J. Neurochem. 95(5), 1461-1471 (2005).
33. Irani DN, Anderson C, Gundry R et al. Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann. Neurol. 59, 237-247 (2006).
34. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics 3, 367-378 (2004). Review of the clinical use of the surface-enhanced laser desorption/ionization time-of-flight method.
35. Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 4, 4, 24 (2003).
36. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl Cancer Inst. 96, 353-356 (2004).
37. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20, 777-785 (2004).
38. Karsan A, Eigl BJ, Flibotte S et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin. Chem. 51, 1525-1528 (2005).
39. Diamandis EP. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem. 49, 1272-1275 (2003).
40. Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer. Lancet 360, 170; author reply 170-171 (2002).
41. Villanueva J, Philip J, Entenberg D et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 76, 1560-1570 (2004).
42. Villanueva J, Philip J, Chaparro CA et al. correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome Res. 4, 1060-1072 (2005). Peptide profiling using bead technology and attention for rigorously standardized conditions and potential sources of patient-related bias.
43. Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 3, 2310-2316 (2003).
44. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 65, 323-332 (2004).
45. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48, 1296-304 (2002).
46. Heine G, Zucht HD, Schuhmann MU et al. High-resolution peptide mapping of cerebrospinal fluid: a novel concept for diagnosis and research in central nervous system diseases. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 782, 353-361 (2002).
47. Stark M, Danielsson O, Griffiths WJ, Jornvall H, Johansson J. Peptide repertoire of human cerebrospinal fluid: novel proteolytic fragments of neuroendocrine proteins. J. Chromatogr. B Biomed. Sci. Appl. 754, 357-367 (2001).
48. Selle H, Lamerz J, Buerger K et al. Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease. Comb. Chem. High Throughput Screen. 8, 801-806 (2005).
49. Dekker LJ, Boogerd W, Stockhammer G et al. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol. Cell. Proteomics 4, 1341-1349 (2005).
50. Dekker L, Römpp A, Taban I et al. Identification of significantly differentially expressed peptides from MALDI-TOF peptide profiles using a combination of MALDI and nano LC ESI-FTMS. ASMS, Seatlle, 2006.
51. Ramstrom M, Ivonin I, Johansson A et al. cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometry. Proteomics 4, 4010-4018 (2004). Fourier transform ion cyclotron resonance described for the analysis of cerebrospinal fluid samples.
52. Ramstrom M, Palmblad M, Markides KE, Hakansson P, Bergquist J. Protein identification in cerebrospinal fluid using packed capillary liquid chromatography Fourier transform ion cyclotron resonance mass spectrometry. Proteomics 3, 184-190 (2003).
53. Mann M. ASMS, TX, USA (2005).
54. Bischoff R, Luider TM. Methodological advances in the discovery of protein and peptide disease markers. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 803, 27-40 (2004).
55. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Natl Cancer Inst. 97, 307-309 (2005).
56. Anderle M, Roy S, Lin H, Becker C, Joho K. Quantifying reproducibility for differential proteomics: noise analysis for protein liquid chromatography-mass spectrometry of human serum. Bioinformatics 20, 3575-3582 (2004).
57. Molloy MP, Donohoe S, Brzezinski EE et al. Large-scale evaluation of quantitative reproducibility and proteome coverage using acid cleavable isotope coded affinity tag mass spectrometry for proteomic profiling. Proteomics 5, 1204-1208 (2005).
58. Bons JA, de Boer D, van Dieijen-Visser MP, Wodzig WK. Standardization of calibration and quality control using surface enhanced laser desorption ionization-time of flightmass spectrometry. Clin. Chim. Acta 366, 249-256 (2006).
59. Dekker LJ, Dalebout JC, Siccama I, Jenster G, Sillevis Smitt PA, Luider TM. A new method to analyze matrix-assisted laser desorption/ionization time-of-flight peptide profiling mass spectra. Rapid Commun. Mass Spectrom. 19, 865-870 (2005).
60. Hong H, Dragan Y, Epstein J et al. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics 6(Suppl. 2), S5 (2005).
61. Hoffmannand E, Stroobant V. Mass spectrometry. Wiley, West Sussex, England, (2002).
62. Bornsen KO. Influence of salts, buffers, detergents, solvents, and matrices on MALDI-MS protein analysis in complex mixtures. Methods Mol. Biol. 146, 387-404 (2000).
63. White CN, Chan DW, Zhang Z. Bioinformatics strategies for proteomic profiling. Clin. Biochem. 37, 636-641 (2004).
64. West-Nielsen M, Hogdall EV, Marchiori E, Hogdall CK, Schou C, Heegaard NH. Sample handling for mass spectrometric proteomic investigations of human sera. Anal. Chem. 77, 5114-5123 (2005).
65. Rai AJ, Gelfand CA, Haywood BC et al. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5, 3262-3277 (2005).
66. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994-999 (1999).
67. Ong SE, Blagoev B, Kratchmarova I et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1, 376-386 (2002).
68. Ishihama Y, Oda Y, Tabata T et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol. Cell. Proteomics 4, 1265-1272 (2005).
69. Zhang J, Goodlett DR, Quinn JF et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis. 7, 125-133 (2005).
70. Zhang J, Goodlett DR, Peskind ER et al. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol. Aging 26, 207-227 (2005).
71. Molloy MP, Donohoe S, Brzezinski EE et al. Large-scale evaluation of quantitative reproducibility and proteome coverage using acid cleavable isotope coded affinity tag mass spectrometry for proteomic profiling. Proteomics 5, 1204-1208 (2005).
72. Anderson L, Hunter CL. Quantitative mass spectrometric MRM assays for major plasma proteins. Mol. Cell. Proteomics 5(4), 573-588 (2006). Applying the multiple reaction monitoring technique for the quantification of peptides.
73. Lee KR, Lin X, Park DC. Megavariate data analysis of mass spectrometric proteomics data using latent variable pojection method. Proteomics 2, 1680-1686 (2003).
74. Ball G, Mian S, Holding F et al. An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 18, 395-404 (2002).
75. Horn DM, Zubarev RA, McLafferty FW. Automated reduction and interpretation of high resolution electrospray mass spectra of large molecules. J. Am. Soc. Mass Spectrom. 11, 320-332 (2000).
76. Yu W, Wu B, Lin N, Stone K, Williams K, Zhao H. Detecting and aligning peaks in mass spectrometry data with applications to MALDI. Comput. Biol. Chem. 30(1), 27-38 (2005).
77. Diamandis EP, van der Merwe DE. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin. Cancer Res. 11, 963-965 (2005).
78. Conrads TP, Anderson GA, Veenstra TD, Pasa-Tolic L, Smith RD. Utility of accurate mass tags for proteome-wide protein identification. Anal. Chem. 72, 3349-3354 (2000).
79. Strittmatter EF, Ferguson PL, Tang K, Smith RD. Proteome analyses using accurate mass and elution time peptide tags with capillary LC time-of-flight mass spectrometry. J. Am. Soc. Mass Spectrom. 14, 980-991 (2003).
80. Smith RD, Anderson GA, Lipton MS et al. The use of accurate mass tags for high-throughput microbial proteomics. Omics 6, 61-90 (2002).
81. Smith RD, Anderson GA, Lipton MS et al. An accurate mass tag strategy for quantitative and high-throughput proteome measurements. Proteomics 2, 513-523 (2002).
82. Pasa-Tolic L, Masselon C, Barry RC, Shen Y, Smith RD. Proteomic analyses using an accurate mass and time tag strategy. Biotechniques 37, 621-624, 626-633, 636 passim (2004). Application of the accurate mass and time tag method for proteomics analysis.
83. Spengler B. De novo sequencing, peptide composition analysis, and composition-based sequencing: a new strategy employing accurate mass determination by Fourier transform ion cyclotron resonance mass spectrometry. J. Am. Soc. Mass Spectrom. 15, 703-714 (2004). Application of high mass accuracy tandem mass spectrometry data for sequencing.
84. Olsen JV, de Godoy LM, Li G et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol. Cell. Proteomics 4, 2010-2021 (2005). New high-resolution and mass accuracy mass spectrometer technique for proteomics analyses.
85. Maciel CM, Junqueira M, Paschoal ME et al. Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J. Exp. Ther. Oncol. 5, 31-38 (2005).